J. J. Molenaar

This study screens cancer drugs to find those that enhance HDR over NHEJ in CRISPR gene editing, identifying Aurora kinase A inhibitors as promising candidates.

The paper identifies prevalent and pathogenic complex structural variations in pediatric solid tumors, linking them to adverse clinical outcomes and potential therapeutic targets.

This study identifies two hepatoblastoma subtypes with distinct WNT activation profiles and discovers drug sensitivities in patient-derived tumor organoids.

The paper identifies two opposing gene expression patterns in ATRX-aberrant neuroblastoma models, suggesting distinct molecular mechanisms and treatment implications.

This study generates tumor organoid models of rhabdomyosarcoma subtypes that closely resemble original tumors and can be used for drug screening and genetic modification.

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

This study identifies PPM1D as an oncogene and therapeutic target in neuroblastoma by showing its role in p53 inactivation and tumor growth.

The paper compares tumor and normal single-cell mRNA data to show neuroblastoma cells resemble fetal sympathoblasts across diverse samples.

The paper identifies MEK inhibition combined with BCL2 family inhibitors as a potent treatment for RAS-MAPK mutated neuroblastoma by stabilizing Bim and increasing sensitivity to Bcl2 inhibitors.